Avelumab and Merkel Cell Carcinoma: Examining Causation and Risk

From General Health Information to Targeted Occupational Inquiry

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic options. Within this broad context, the transition from population-level health guidance to specific occupational exposure concerns requires careful attention to emerging pharmaceutical evidence. Avelumab, a programmed death-ligand 1 (PD-L1) blocking antibody, has been studied extensively in oncology, particularly for its role in treating Merkel cell carcinoma. As clinical data accumulate, attention has turned to understanding the relationship between avelumab exposure and the risk of developing Merkel cell carcinoma itself. This shift in focus—from general health information to a more targeted inquiry—mirrors the broader movement in occupational health toward identifying specific chemical or pharmaceutical exposures that may contribute to disease risk. The question of causation, rather than mere association, becomes paramount when considering workplace or environmental exposure scenarios. For professionals in manufacturing, healthcare, or research settings where avelumab is handled or administered, understanding the potential risk profile is essential. This pivot from general health literacy to occupational exposure concern underscores the need for rigorous epidemiological investigation and risk communication strategies that address both therapeutic benefits and potential hazards.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Evidence on Avelumab and Risk of Merkel Cell Carcinoma

Regarding causation-related considerations, the evidence indicates that avelumab is used as a treatment for Merkel cell carcinoma, not as a cause of the disease. The risk narrative centers on the adequacy of warnings about avelumab's efficacy and adverse effects in the context of MCC treatment. The standard treatment of metastatic MCC is the use of anti-PD-1/-PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, the risk of non-response or progression on therapy is substantial, with approximately 50% of patients not responding or developing immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). The timeline between exposure to avelumab and documented harm is not explicitly detailed in the provided evidence, but the studies describe outcomes in patients who were refractory to avelumab, indicating that harm (progression or lack of response) can occur during or after treatment. The evidence does not suggest a causal link between avelumab and the development of Merkel cell carcinoma; rather, avelumab is a therapeutic agent for an existing diagnosis.

Management of Avelumab-Refractory Merkel Cell Carcinoma

For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory Merkel cell carcinoma (https://pubmed.ncbi.nlm.nih.gov/36450381/). In a retrospective study at three different sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab/nivolumab were collected (https://pubmed.ncbi.nlm.nih.gov/33439294/). Five patients were enrolled, and three out of five responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A separate retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory Merkel cell carcinoma also examined outcomes in this population (https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence supports that avelumab is an approved and effective treatment for metastatic Merkel cell carcinoma, with a significant proportion of patients achieving objective responses. However, a substantial subset of patients does not respond or experiences progression, and for these avelumab-refractory patients, alternative treatments such as ipilimumab plus nivolumab may offer benefit. The risk considerations for affected patients include the potential for lack of response, immune-related adverse events, and the need for subsequent therapies. The adequacy of warnings regarding avelumab and Merkel cell carcinoma should reflect these efficacy and safety profiles, as established in clinical trials and real-world studies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. The evidence indicates that avelumab is used to treat metastatic Merkel cell carcinoma and does not suggest a causal link between avelumab exposure and the development of the disease.

What are the risks of avelumab treatment for Merkel cell carcinoma?

The primary risks include lack of response (approximately 50% of patients do not respond or progress on therapy) and immune-related adverse events. For patients who are refractory to avelumab, alternative treatments such as ipilimumab plus nivolumab may be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.